Subtype
Urinary Tract Carcinoma
CI-CAN-00007014Explore in graph →
327 active trials11 approved drugs23 evidence items
- NCIt
- C192669
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007014Explore in graph →
Clinical trials
853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (127)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03121768 | A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | unknown | — | 761 | Mansoura UniversityOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT01328574 | TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT00565227 |
| Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. |
| terminated |
| Phase 1 |
| 12 |
| University of Michigan Rogel Cancer CenterOTHER |
| 1 |
| Dec 2, 2016 |
| clinicaltrials |
| NCT02923557 | Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients | unknown | Phase 2 | 200 | Peking University First HospitalOTHER | 1 | Nov 17, 2016 | clinicaltrials |
| NCT02589717 | An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00362713 | Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection | completed | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT01606345 | Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma | completed | Phase 1 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT01182168 | Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00469066 | Cone Beam CT Scanning in Lung and Bladder Cancer. | completed | — | 22 | AHS Cancer Control AlbertaOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT00588666 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT01599013 | JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin(JASINT1) | completed | Phase 2 | 69 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT02547350 | Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas | unknown | Phase 2 | 200 | Xuesong LiOTHER | 0 | Sep 11, 2015 | clinicaltrials |
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | Hoosier Cancer Research NetworkOTHER | 0 | Aug 19, 2015 | clinicaltrials |
| NCT00734994 | Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer | completed | Early Phase 1 | 15 | Mark DewhirstOTHER | 1 | Jun 29, 2015 | clinicaltrials |
| NCT01600339 | A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) | completed | Phase 2 | 19 | Rambam Health Care CampusOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT02278978 | BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma | unknown | Phase 2 | 129 | National Taiwan University HospitalOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT01526486 | Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer | completed | N/A | 29 | Emory UniversityOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT02007005 | Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 37 | Abnoba GmbhINDUSTRY | 2 | May 6, 2015 | clinicaltrials |
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2015 | clinicaltrials |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00407485 | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT01487915 | Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma(COACH) | unknown | Phase 2 | 80 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01490437 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma(PECULIAR) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00471536 | Pazopanib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | May 30, 2014 | clinicaltrials |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 0 | Apr 29, 2014 | clinicaltrials |
| NCT01304173 | Retrospective Chart Review of Valstar | completed | — | 113 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01993966 | EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells | unknown | — | 25 | National Taiwan University HospitalOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01968928 | The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma | unknown | — | 25 | National Taiwan University HospitalOTHER | 1 | Oct 28, 2013 | clinicaltrials |
| NCT01939756 | Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms(Baobab) | completed | Phase 1 / Phase 2 | 50 | Savino M. Di StasiOTHER | 1 | Sep 11, 2013 | clinicaltrials |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00021099 | Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005831 | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT01245660 | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy(LAPAINBLAD) | terminated | Early Phase 1 | 3 | University Hospital, BordeauxOTHER | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00322699 | Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 22 | North Florida/South Georgia Veterans Health SystemOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT00867633 | Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan | unknown | — | 100 | National Taiwan University HospitalOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT01149174 | Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer(EMDA/PRE-TUR) | completed | Phase 3 | 352 | University of Rome Tor VergataOTHER | 1 | Oct 4, 2011 | clinicaltrials |
| NCT01378052 | DNA Methylation and Urothelial Carcinoma | unknown | — | 200 | China Medical University HospitalOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT01360723 | DNA Methylation and Arsenic-associated Urothelial Carcinoma | unknown | — | 600 | China Medical University HospitalOTHER | 1 | May 27, 2011 | clinicaltrials |
| NCT00330707 | Combined Use of BCG and Interferon Alpha in Bladder Cancer | completed | Phase 2 / Phase 3 | 140 | National University Hospital, SingaporeOTHER | 1 | Mar 4, 2011 | clinicaltrials |
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
| NCT00782587 | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer(IPOP) | completed | Phase 1 | 14 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 8, 2010 | clinicaltrials |
| NCT00315237 | Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract | completed | Phase 3 | 364 | Pierre Fabre MedicamentINDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00854464 | Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma | unknown | — | 420 | National Taiwan University HospitalOTHER | 1 | Mar 3, 2009 | clinicaltrials |
Data updated 23 days agoSource updated May 16, 2017source: clinicaltrials